奥马佐单抗
医学
慢性荨麻疹
养生
重症监护医学
慢性病
人口
儿科
免疫球蛋白E
免疫学
外科
环境卫生
抗体
作者
Ioana Agache,Cezmi A. Akdiş,Knut Brockow,T. Chivato,Stefano Del Giacco,Thomas Eiwegger,Kilian Eyerich,Ana Giménez‐Arnau,Jan Gutermuth,Emma Guttman‐Yassky,Marcus Maurer,Graham S. Ogg,Peck Y. Ong,Liam O’Mahony,Jürgen Schwarze,Amena Warner,Thomas Werfel,Óscar Palomares,Marek Jutel
出处
期刊:Allergy
[Wiley]
日期:2021-08-08
卷期号:77 (1): 17-38
被引量:18
摘要
Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI